Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity.
The attempts to find an effective antituberculous subunit vaccine are based on the assumption that it must drive a Th1 response. In the absence of effective correlates of protection, a vast array of mycobacterial components are being evaluated worldwide either on the basis of their ability to be recognized by T lymphocytes in in vitro assays during early stage of animal or human infection (antigenicity) or their capacity to induce T cell response following immunization in animal models (immunogenicity). The putative vaccine candidates selected using either of these strategies are then subjected to challenge studies in different animal models to evaluate the protective efficacy. Here we review the outcome of this current scheme of selection of vaccine candidates using an 'antigenicity' or 'immunogenicity' criterion on the actual protective efficacy observed in experimental animal models. The possible implications for the success of some of the leading vaccine candidates in clinical trials will also be discussed.
Sable
Suraj B
SB
Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh-160 012, India. dpt7@cdc.gov
Kalra
Mamta
M
Verma
Indu
I
Khuller
G K
GK
D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology*; D004195:Disease Models, Animal; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000276:immunology*; D015202:Protein Engineering; D014376:Tuberculosis / Q000276:immunology / Q000517:prevention & control*; D032581:Tuberculosis Vaccines / Q000138:chemical synthesis / Q000276:immunology*; D022223:Vaccines, Subunit / Q000138:chemical synthesis / Q000276:immunology
D000942:Antigens, Bacterial; D032581:Tuberculosis Vaccines; D022223:Vaccines, Subunit